Obesity and type 2 diabetes (T2D) are burgeoning global health challenges characterized by chronic inflammation and metabolic dysfunction. Macrophages, key immune cells infiltrating adipose tissue, play a pivotal role in orchestrating this inflammatory response. Recent research has spotlighted glutamine metabolism as a novel avenue in understanding macrophage biology and its implications in obesity-related metabolic derangements [1]. This article reviews the emerging role of glutamine metabolism in macrophages and explores its potential as a therapeutic target for alleviating inflammation and improving insulin sensitivity in the context of obesity and T2D. By deciphering the intricate interplay between glutamine metabolism and macrophage function, we can envisage innovative strategies to combat the obesity-T2D continuum [2].
